Introduction
Cholestatic pruritus (itch) is common in primary biliary cholangitis (PBC) and is associated with significantly impaired quality of life. Lysophosphatidic acid (LPA) and bile acids may have a pathophysiological role in pruritus. Autotaxin (ATX) is the primary enzyme that produces LPA and is a surrogate for LPA levels. ATX activity correlates with itch intensity in PBC. Linerixibat is a minimally absorbed, small-molecule ileal bile acid transporter inhibitor that improves pruritus and reduces systemic bile acid levels, ATX, and fibroblast growth factor-19 (FGF-19), a downstream effector of farnesoid X receptor activation and regulator of bile acid biosynthesis.1 Here, we analyze the association between itch response and changes in ATX and FGF-19 biomarker levels following linerixibat treatment.
Aims & Methods
The Phase 2b, placebo-controlled, dose-ranging GLIMMER study (NCT02966834) enrolled 147 adult patients with PBC and pruritus.1 Patients were randomized to receive linerixibat or placebo for 12 weeks (Weeks 4–16). Patients reported itch on a 0–10 numerical rating scale. As patient numbers were too low to analyze biomarkers in individual dose groups, the two twice daily (BID) dose groups, 40 and 90 mg BID, which showed a greater response in pharmacodynamic biomarkers compared to once daily dosing, were combined. Serum ATX and FGF-19 levels were compared post hoc in patients receiving linerixibat 40/90 mg BID or placebo, at baseline versus Week 16, in itch responders and non-responders. Responder analysis from individual dose groups is not shown. Itch responders were defined as patients with a monthly itch score improvement of ≥2 at Week 16 compared with baseline.
Results
Patients treated with linerixibat 40/90 mg BID (n=45), or placebo (n=36) were included; baseline demographics have been reported previously.1 Itch responders in the 40/90 mg BID group, but not in the placebo group, had greater reductions in serum ATX at Week 16 compared with baseline. In linerixibat-treated patients, ATX levels at Week 16 were reduced in itch responders compared to non-responders, and in comparison with placebo. Similarly, FGF-19 reduction was associated with itch response in patients receiving linerixibat 40/90mg BID compared with placebo.
Conclusion
Serum ATX and FGF-19 may function as biomarkers of itch response to linerixibat treatment. Reductions in these biomarkers are associated with clinical response in patients with PBC and pruritus.
Funding: GSK (201000).
Encore statement: This abstract was originally presented as poster 4574-C at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting on November 13, 2023; this encore is presented on behalf of the original authors with their permission.
Disclosure
SM, LC, BS and MMM are employees of, and hold stocks/shares in, GSK. JF is a former employee of, and holds stocks/shares in, GSK. SD is an employee of GSK. AEK reports grant/research support from Intercept Pharmaceuticals and Gilead, and speaker/consultancy fees from AbbVie, Bristol Myers Squibb, CymaBay Therapeutics, Eisai, Escient, Falk, Gilead, GSK, Intercept Pharmaceuticals, Janssen, Lilly, Mirum, MSD, Vifor, and Zambon.